

line 17, change "(gag" to --(gag--; and

line 24, after "etc." delete the period.

Page 14, line 7, change "above mentioned" to --above-mentioned--;

line 9, after "Finally" insert a comma;

line 12, after "tides" insert a comma;

line 20, change "nucleotidic" to --nucleotide--;

line 21, change "nucleotidic" to --nucleotide--;

line 26, change "INSTITUT PASTEUR of Pasteur (France)" to --Institut Pasteur, 28 Rue du Docteur Roux, 75724 Paris Cedex 15, France,--;

line 30, change "aminoacid" to --amino acid--; and

line 34, change "bracketted" to --bracketed--.

IN THE CLAIMS:

Please cancel claims 1-22 without prejudice or disclaimer of the material claimed therein and add the following claims.

Subst. C1
--23. A method of producing antibodies to a lymphadenopathy associated virus antigen,

B5
wherein said antigen is the expression product of a host transformed with a vector containing a DNA fragment of plasmid λ -J19, and

wherein said DNA fragment comprises the restriction sites *HindIII*, and *SacI*, and a first *BglIII* restriction site, from the 3' end to the 5' end,

said method comprising expressing antigens encoded by said DNA fragment and raising antibodies against said antigens.

24. The method of claim 23, wherein said DNA fragment further comprises, after said first *Bgl*III restriction site, a second *Bgl*III restriction site and a *Kpn*I restriction site from said 3' end to said 5' end.

25. The method of claim 24, wherein said DNA fragment further comprises, after said *Kpn*I restriction site, the restriction sites *Xho*I, *Bam*HI, and *Hind*III, and a third *Bgl*III restriction site from said 3' end to said 5' end.

26. Antibodies to a lymphadenopathy associated virus (LAV) antigen,

wherein said antigen is the expression product of a host transformed with a vector containing a DNA fragment of plasmid λ -J19, and

wherein said DNA fragment comprises the restriction sites *Hind*III and *Sac*I, and a first *Bgl*III restriction site, from the 3' end to the 5' end.

27. The antibodies of claim 26, wherein said DNA fragment further comprises, after said first *Bgl*III restriction site, a second *Bgl*III restriction site and a *Kpn*I restriction site from said 3' end to said 5' end.

28. The antibodies of claim 27, wherein said DNA fragment further comprises, after said *Kpn*I restriction site, the restriction sites *Xho*I, *Bam*HI, and *Hind*III, and a third *Bgl*III restriction site from said 3' end to said 5' end.

29. A method for detecting antibodies to a lymphadenopathy associated virus (LAV) antigen,